Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsWPS Health Insurance Prior Auth & Coding Policy Up…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentWPS Health InsurancePolicy N/A

    Drug Prior Authorization Requirements (Pharmacy & Medical Benefit)

    Customize your policy alerts

    Sign up for all WPS Health Insurance policy alerts

    Know when WPS Health Insurance releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization (PA) requirements for pharmacy and medical benefit drugs managed by WPS Health Insurance and delegated reviewers (Express Scripts, Care Continuum, eviCore), and explains submission routing and resources for providers and members.

    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug Prior Authorization Requirements (Pharmacy & Medical Benefit)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request to the designated reviewer (ESI, CCUM, eviCore, or WPS) using the provided contact routing and include drug name, HCPCS/J-code, benefit type, and indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All drugs on listRequire prior authorization
    1-800-475-1954Primary reviewer phone
    4/1/2026Effective date
    MultipleHCPCS codes

    Coverage Criteria and Requirements

    General prior authorization requirement

    Covered when PA is obtained and medical necessity met.

    General PA requirement: All drugs listed require prior authorization regardless of condition; PA reviewers are specified per drug entry (WPS, ESI, CCUM, eviCore).

    Providers must submit requests to the designated reviewer; if the delegated reviewer cannot complete the review, submit to WPS or the group's PBM as instructed.

    Coverage contingent on prior authorization

    Covered when prior authorization is obtained and reviewed by the assigned reviewer.

    PA requirement: The drug is covered only if prior authorization is obtained and approved by the assigned reviewer (Express Scripts/ESI, Care Continuum/CCUM, eviCore, or WPS).

    If the group's PBM other than ESI is used, submit to that PBM; if external reviewers cannot complete the review, submit to WPS for evaluation.

    General prior authorization routing requirement

    Covered when PA is obtained and reviewer routing is followed.

    PA routing requirement: Drug is on the listed PA-required drugs and a prior authorization must be submitted to the designated reviewer (ESI, CCUM, eviCore, or WPS).

    Include drug name, applicable HCPCS/J-code, benefit type (Pharmacy or Medical), and indicate oncology vs non-oncology to route to the correct reviewer; if the delegated reviewer cannot complete the review, submit to WPS.

    Services determined to be experimental, investigational, and/or unproven under the plan's clinical guidelines are not covered. Coverage of all services is subject to medical necessity, and treatments that do not meet medical necessity criteria may be denied.

    All drugs listed in the document excerpts require prior authorization (PA). Each drug entry identifies the assigned reviewer (Express Scripts/ESI, Care Continuum/CCUM, eviCore, or WPS) and, where applicable, the HCPCS/J-code and benefit type (Pharmacy or Medical). If an external reviewer (ESI, CCUM, or eviCore) cannot complete the review, providers must submit the PA to WPS for evaluation.

    Where noted, the policy reiterates: “PLEASE NOTE: All drugs on this list require a PA.” and includes reviewer contact routing and effective dates for the listed entries (for example, Effective Date: 4/1/2026).

    Drug list entries include the billed benefit type — shown as Pharmacy (P) or Medical (M) — and indicate the designated reviewer for PA routing (ESI, CCUM, eviCore, or WPS). These entries do not provide indication‑specific clinical coverage criteria in the cited segments; they primarily document billing classification and reviewer assignment.

    Providers should use the listed HCPCS/J-codes when submitting medical-benefit PA requests and follow the reviewer routing shown for each drug.

    If the member’s group uses a PBM other than Express Scripts (ESI) through WPS, submit pharmacy‑benefit PA requests to that PBM. This instruction applies even when a drug is listed in sections otherwise routed to ESI or eviCore; when an external reviewer cannot complete the review, submit the PA to WPS for evaluation.

    No additional clinical exclusion conditions are specified in these excerpts. The document reiterates the PA requirement across multiple drug entries and supplies reviewer routing, HCPCS/J-codes, and benefit type, but does not list indication‑specific denials or not‑medically‑necessary conditions in the cited segments.

    The policy repeats that all drugs on the list require prior authorization. Specific entries reiterate PA routing to the named reviewer or to WPS (when delegated reviewers cannot complete the review). Providers must follow the reviewer assignment and include relevant HCPCS/J-codes and benefit type when submitting the PA.

    Where a PBM other than ESI is used through WPS, providers should submit PA requests to that PBM for pharmacy‑benefit drugs. The document consistently notes this routing and advises submission to WPS if delegated reviewers cannot complete the review.

    If provider or group PBM arrangements differ from the listed reviewer routing (for example, the group uses a PBM other than ESI), the PA should be submitted to the group’s PBM. If an external reviewer is unable to complete the evaluation, submit the PA to WPS for final review.

    Coverage for listed drugs is contingent on meeting medical necessity and obtaining an approved prior authorization. Review decisions are made by clinicians employed by WPS or by delegated reviewers (Express Scripts/ESI, Care Continuum/CCUM, and eviCore) who use medical records, FDA labeling, peer‑reviewed literature, and evidence‑based guidelines to determine necessity. Treatments that do not meet medical necessity may be denied.

    No explicit 'not medically necessary' conditions are listed in the cited excerpts. The document emphasizes that PA is required for all listed drugs and that failure to obtain PA may result in denial, but indication‑specific NMN examples are not present in these segments.

    HCPCS / J-Codes and Billing Codes

    Listed HCPCS/other codes from policy excerptsHCPCS
    J3490Used for multiple topical/other drugs (example: 5-fluorouracil - topical)
    J91905-fluorouracil - injection
    J8499Miscellaneous HCPCS for certain oral/other drugs (example: abacavir/dolutegravir/lamivudi)
    J0129Abatacept
    J8999Oral antineoplastic/other misc code (used for several oral oncology agents)
    Q5131Adalimumab-aacf biosimilar
    Q5144Adalimumab-aacf biosimilar
    J0135Adalimumab (originator) HCPCS
    J0139Adalimumab product code variant
    Q5141Adalimumab-aaty biosimilar
    1–10 of 19
    1/2
    Sample HCPCS codes from list (partial)HCPCS
    J3490adapalene/benzoyl peroxide; albuterol inhaler; amikacin liposomal/neb.accessr (listed as J3490 in file)
    J9354ado-trastuzumab emtansine
    J0172aducanumab-avwa
    Biosimilar HCPCS codesHCPCS
    Q5149aflibercept-abzv (biosimilar)
    Q5147aflibercept-ayyh (biosimilar)
    C9161aflibercept (HD) additional code
    Hemophilia factor HCPCS codesHCPCS
    J7185antihemophil.fviii (various recombinant/full length) - listed multiple times
    J7192antihemophil.fviii / antihemophilic factor (various) - listed
    J7190antihemophilic factor (human)
    J7182antihemophilic factor (recombinant) NOVOEIGHT
    Sample HCPCS codes from entriesHCPCS
    J7192antihemophil.fviii, full length (ADVATE) / antihemophilic factor (recombinant) listed
    Sample HCPCS codes from list (partial)HCPCS
    J7192antihemophil.fviii, full length (ADVATE) / antihemophilic factor (recombinant) listed
    Antihemophilic factor HCPCS codesHCPCS
    J7182antihemophilic factor (recombinant) NOVOEIGHT
    J7185antihemophilic factor (recombinant) XYNTHA
    J7192antihemophilic factor (recombinant) HELIXATE FS / KOGENATE FS / RECOMBINATE
    J7211antihemophilic factor (recombinant) KOVALTRY
    Human antihemophilic factor HCPCSHCPCS
    J7190antihemophilic factor, human (HEMOFIL M, KOATE, KOATE-DVI)
    J7191antihemophilic factor, human / MONOCLATE-P
    Antihemophilic factor/vWF HCPCSHCPCS
    J7183antihemophilic factor/vwf WILATE
    J7186antihemophilic factor/vwf ALPHANATE
    J7187antihemophilic factor/vwf HUMATE-P
    Hemostasis agents HCPCSHCPCS
    J7188antihemophilic fviii, recombinant porcine (OBIZUR)
    J7198anti-inhibitor coagulant component (FEIBA)
    Mixed HCPCS codes (sample)HCPCS
    J7511anti-thymocyte globulin, rabbit (THYMOGLOBULIN)
    J8999apalutamide - oral (ERLEADA) - listed with J8999
    J8499apixaban (ELIQUIS) listed with J8499
    J3490apomorphine listed with J3490 / J3590
    Additional HCPCS/CodesHCPCS
    C9399apomorphine other code listed
    J0364apomorphine hcl (KYNMOBI, APOKYN)
    J3590apremilast (OTEZLA)
    Aprepitant IV codesHCPCS
    J8502aprepitant - IV (CINVANTI) listed with J8502
    C9145aprepitant - IV possible alternate
    C9463aprepitant - IV alternate
    J0185aprepitant - IV alternate billing
    Single-entry codesHCPCS
    J8499armodafinil listed with J8499
    Oncology and enzyme therapy HCPCSHCPCS
    J9017arsenic trioxide (TRISENOX)
    J8999asciminib - oral (SCEMBLIX)
    J3490asfotase alfa (STRENSIQ) listed with J3490 / J3590
    J9021asparaginase erwinia chrysanthemi (RYLAZE)
    Atezolizumab codesHCPCS
    J9022atezolizumab (TECENTRIQ)
    J9024atezolizumab and hyaluronidase-tqjs (TECENTRIQ HYBREZA)
    Varied therapies HCPCSHCPCS
    J3391atidarsagene autoemcel (LENMELDY) gene therapy
    J8499atogepant listed with J8499
    J8499atorvastatin/ezetimibe listed with J8499
    Ophthalmology and other agentsHCPCS
    J8499auranofin listed with J8499
    J2782avacincaptad pegol (IZERVAY)
    C9162avacincaptad pegol alternate
    Enzyme replacement and targeted therapy codesHCPCS
    J0219avalglucosidase alfa-ngpt (NEXVIAZYME)
    J8999avapritinib - oral (AYVAKIT)
    J8499avatrombopag maleate listed with J8499
    Immunotherapy and CAR-T codesHCPCS
    J9023avelumab (BAVENCIO)
    J9038axatilimab-csfr (NIKTIMOVO)
    Q2041axicabtagene ciloleucel (YESCARTA)
    Targeted and oncology codesHCPCS
    J8999axitinib - oral listed with J8999
    J9025azacitidine (VIDAZA)
    Topical / nasal product codesHCPCS
    J3490azelaic acid (AZELEX, FINACEA) and azelastine entries
    Additional HCPCS codesHCPCS
    J8499azilsartan, azilsartan/chlorthalidone, aztreonam lysine, baricitinib, and others listed with J8499
    J3490aztreonam lysine (CAYSTON) listed with J3490
    J9030BCG (THERACYS, TICE)
    Sample HCPCS from chunk 54HCPCS
    J8499azilsartan (listed HCPCS)
    HCPCS examples from chunk 55HCPCS
    J9030bcg
    HCPCS examples from chunk 59HCPCS
    J0517benralizumab
    Bevacizumab codes (chunk 61)mixed
    C9257bevacizumab (listed HCPCS)
    J9035bevacizumab
    Misc HCPCS codes (chunk 65)HCPCS
    J3590brolucizumab / brodalumab type (used in document)
    J3490miscellaneous injectable drug code (used for several nasal/topical entries)
    J9999miscellaneous code shown with bevacizumab-tnjn
    J3590bevacizumab-tnjn (also listed)
    Oncology HCPCS codes (chunks 66-67)HCPCS
    J9041bortezomib
    J9039blinatumomab
    Brentuximab code (chunk 70)HCPCS
    J9042brentuximab vedotin
    CAR-T and infusion codes (chunk 71)mixed
    J1632brexanolone
    C9073brexucabtagene autoleucel
    Q2053brexucabtagene autoleucel
    Oral drug HCPCS placeholders (chunk 72)HCPCS
    J8999brigatinib - oral (listed HCPCS placeholder)
    Misc codes (chunk 73)HCPCS
    J8499bupropion (listed HCPCS placeholder)
    J0584burosumab-twza
    Sample HCPCS codes from list (partial)HCPCS
    J8999HCPCS code listed for brigatinib (oral) and used as general misc oral drug code in entries
    J8499HCPCS code used for multiple pharmacy-benefit drugs (e.g., brivaracetam, budesonide entries)
    J3590HCPCS code listed for brodalumab
    J0179HCPCS code listed for brolucizumab-dbll
    HCPCS codes (partial)HCPCS
    J0739HCPCS code for cabotegravir (APRETUDE)
    J0741HCPCS code for cabotegravir/rilpivirine extended-release injection (CABENUVA)
    J9043HCPCS code for cabazitaxel
    J8999HCPCS code for cabozantinib - oral
    HCPCS/Q-codes (partial)HCPCS
    J0638HCPCS code for canakinumab (ILARIS)
    J8499HCPCS code for cannabidiol (EPIDIOLEX) entry
    J9118HCPCS code for calaspargase pegol-mknl (ASPARLAS)
    Q0240HCPCS (Q-code) for casirivimab/imdevimab (EUA)
    Q0243HCPCS (Q-code) for casirivimab/imdevimab (EUA)
    Q0244HCPCS (Q-code) for casirivimab/imdevimab (EUA)
    HCPCS codes (additional)HCPCS
    J9045HCPCS code for carboplatin
    J9047HCPCS code for carfilzomib
    J0725HCPCS code for chorionic gonadotropin
    J9055HCPCS code for cetuximab
    Sample group (partial) - multiple drugs and codes listed across chunksHCPCS
    J3490ciprofloxacin otic (listed with HCPCS J3490 in this segment)
    J9060cisplatin
    J8499cladribine (and multiple other drugs assigned J8499)
    Covered HCPCS/J-codes listed in this segmentHCPCSCovered
    J7213coagulation factor ix (recombinant)
    J7189coagulation factor viia, recomb
    J7175coagulation factor x
    J7212coagulation viia, recomb-jncw
    J8999multiple oral oncology agents and others (listed as J8999)
    J0775collagenase clostridium hist.
    J7173concizumab
    J0800corticotropin
    J0850cytomegalovirus immune globulin (CYTOGAM)
    J9100cytarabine
    1–10 of 22
    1/3
    Sample listed HCPCS/Codesmixed
    C9174datopotamab deruxtecan-dlnk, Reviewer ESI, CCUM, eviCore
    J9150daunorubicin (HCPCS Code listed)
    J9153daunorubicin/cytarabine liposome (VYXEOS) HCPCS Code
    J0589daxibotulinumtoxinA-lanm HCPCS Code
    Additional HCPCS/Codesmixed
    J0894decitabine HCPCS Code
    J0893decitabine (sun pharma) HCPCS Code
    J8999decitabine and cedazuridine - oral, HCPCS Code (J8999)
    J9000doxorubicin hcl HCPCS Code
    Gene therapy / biologics codesmixed
    J1413delandistrogene moxeparvovec-rokl (ELEVIDYS) HCPCS Code
    J9161denileukin diftitox-cxdl HCPCS Code
    J0897denosumab HCPCS Code
    C9399denosumab-bbdz HCPCS Code listed for biosimilars

    Provider Submission, Routing, and Operational Notes

    Prior Authorization

    Prior authorization required for listed drugs

    All drugs listed on the policy require prior authorization; submit the PA using the HCPCS/J-code shown for the drug and route the request to the reviewer indicated (ESI, CCUM, eviCore) or to WPS if the external reviewer cannot complete the review.

    • Include the drug name and appropriate HCPCS/J-code when submitting the PA.
    • Use reviewer contact 1-800-475-1954 for ESI/CCUM/eviCore or WPS at 1-800-333-5003 when routing as directed.
    Prior Authorization

    PA required for listed drugs

    Prior authorization is required for each drug listed; the policy indicates the assigned reviewer (ESI, CCUM, eviCore) and the HCPCS code to use per drug entry.

    • Follow the reviewer assignment shown next to each drug (e.g., ESI = option 1, CCUM = option 2, eviCore = option 3).
    • If your group's PBM is not ESI through WPS, submit to that PBM as instructed.

    Initial Prior Authorization and Routing

    Initial prior authorization routing

    How to request initial therapy.

    Initial PA process: Submit a prior authorization request to the specified reviewer (ESI, CCUM, eviCore) using the contact information provided; if the external reviewer cannot complete the review, submit to WPS for evaluation. For drugs reviewed by Express Scripts or Care Continuum call 1-800-475-1954. For eviCore criteria see evicore.com (search 'WPS Health Insurance').

    Confirm gene therapy coverage with WPS Customer Service using the number on the member's insurance card.

    Step therapy / initial therapy entry (reference to reviewer-supplied criteria)

    Step therapy criteria and prior authorization details are available from reviewers.

    Step therapy access: Step therapy criteria and detailed prior authorization requirements for drugs reviewed by Express Scripts or Care Continuum are available by calling 1-800-475-1954; eviCore clinical guidelines are available at evicore.com.

    If the group's PBM other than ESI is handling benefits through WPS, submit step therapy/PA requests to that PBM as applicable.

    Step Therapy Details

    StepRequirement / Where to obtain details
    1
    Step therapy criteria and detailed prior authorization criteria for drugs reviewed by Express Scripts (ESI) or Care Continuum (CCUM) are available by calling 1-800-475-1954; for drugs reviewed by eviCore, see https://www.evicore.com/provider/clinical-guidelines and search for 'WPS Health Insurance'.
    StepPBM submission guidance
    1
    If the group uses a PBM other than Express Scripts (ESI) through WPS, submit prior authorization and step therapy requests to that PBM; this includes pharmacy drugs that may otherwise be reviewed by ESI or eviCore.
    StepPBM submission guidance (repeated)
    1
    If using a PBM other than ESI through WPS, submit to the other PBM (including pharmacy drugs reviewed by ESI or eviCore).
    StepPBM submission guidance (repeated)
    1
    If using a PBM other than ESI through WPS, submit to the other PBM (including pharmacy drugs reviewed by ESI or eviCore).

    Sites of Care and Setting Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Biosimilar Entries and Routing

    Note
    Note
    Note
    Note

    Key Definitions and Reviewer Codes

    Benefit Type
    DefinitionIndicates whether the drug is billed under Pharmacy (P) or Medical (M) benefit as listed per drug entry.
    LocationBenefit Type appears next to each drug entry (e.g., 'Benefit Type P = Pharmacy** M = Medical = P').
    UseDetermines billing pathway and whether HCPCS codes are used for facility/provider billing.
    Reviewers
    Who are reviewersWPS, Express Scripts (ESI), Care Continuum (CCUM), and eviCore perform prior authorization reviews.
    Routing depends onDrug and group configuration; the prior authorization list specifies the reviewer per drug.

    Background and Purpose

    Prior authorization is used to ensure appropriate use of certain drugs and to confirm medical necessity. Review decisions are made by clinicians (physicians, nurses, and pharmacists) employed by the plan or by delegated partners (ESI, CCUM, eviCore). Reviewers rely on the patient's medical records, prior treatments, FDA labeling, peer‑reviewed literature, and evidence‑based guidelines when evaluating PA requests.

    For drugs reviewed by Express Scripts or Care Continuum, step therapy and detailed PA criteria are available by calling 1-800-475-1954 or by consulting the delegated reviewer’s published guidelines. For AETNA network groups, medical‑benefit drugs may require pre‑review via fax to American Health Holdings per the instructions provided in the policy.

    Policy Summary
    PayerWPS Health Insurance
    PolicyDrug Prior Authorization Requirements (Pharmacy & Medical Benefit)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request to the designated reviewer (ESI, CCUM, eviCore, or WPS) using the provided contact routing and include drug name, HCPCS/J-code, benefit type, and indication.
    SourceLink
    On This Page
    Coverage Criteria and RequirementsHCPCS / J-Codes and Billing CodesProvider Submission, Routing, and Operational NotesInitial Prior Authorization and RoutingStep Therapy DetailsSites of Care and Setting NotesBiosimilar Entries and RoutingKey Definitions and Reviewer CodesBackground and Purpose
    Oncology drug HCPCS codesmixed
    J1246dinutuximab HCPCS Code
    J9171docetaxel HCPCS Code
    J9174docetaxel (beizray) HCPCS Code
    Q2050doxorubicin hcl (liposomal) HCPCS Code
    Listed HCPCS/J-codes (sample from chunk 126)HCPCS
    J8499droxidopa (listed with HCPCS J8499 in this section)
    J3490dulaglutide (listed with HCPCS J3490)
    J3590dupilumab (listed with HCPCS J3590)
    J9173durvalumab (listed with HCPCS J9173)
    Listed HCPCS/J/Q-codes (sample from chunks 127-128)HCPCS
    J8999duvelisib - oral (J8999) and other oral oncology agents
    J1290ecallantide (J1290)
    J1299eculizumab (J1299)
    J1300eculizumab (J1300)
    Q5151eculizumab-abzv biosimilar (Q5151)
    Q5139eculizumab-aeeb biosimilar (Q5139)
    J1301edaravone (J1301)
    C9493edaravone (C9493)
    J9361efbemalenograstim alfa-vuxw (J9361)
    J9334efgartigimod alfa and hyaluronidase-qvfc (J9334)
    1–10 of 12
    1/2
    Additional HCPCS/J/C/Q codes (chunks 131-145)HCPCS
    J3387elivaldogene autotemcel (J3387)
    C9399eladocagene exuparvovec-tneq (C9399)
    J8499elagolix, elbasvir/grazoprevir, eletriptan, elexacaftor/tezacaftor/ivacaftor, eliglustat tartrate, eltrombopag, empagliflozin, etc. (J8499 used for many)
    J1322elosulfase alfa (J1322)
    J9176elotuzumab (J9176)
    J1323elranatamab-bcmm (J1323)
    C9165elranatamab-bcmm (C9165)
    J3032eptinezumab-jjmr (J3032)
    J7170emicizumab-kxwh (J7170)
    Q9995emicizumab-kxwh (Q9995)
    1–10 of 15
    1/2
    Covered HCPCS Codes (excerpt)HCPCS
    J9179eribulin mesylate
    J8999erlotinib - oral (listed under HCPCS as J8999)
    Covered HCPCS Codes (excerpt)HCPCS
    J0013esketamine (listed as J0013 / S0013 across chunks)
    S0013esketamine (alternate code listed)
    Covered HCPCS Codes (additional excerpt)HCPCS
    J1305evinacumab-dgnb
    J9358fam-trastuzumab deruxtecan-nxki
    Covered HCPCS Codes (factor products)HCPCS
    J7194factor ix cplx(pcc)no4, 3factor
    J7203factor ix human rec, pegylated / factor ix human recombinant
    J7199factor ix recom, albumin fusion (J7199 J7202)
    J7214factor VIII, recombinant human with VWF fusion
    Covered HCPCS/Q Codes (blood products / filgrastim)mixed
    J7177fibrinogen
    J7178fibrinogen concentrate (human)
    J1442filgrastim
    Q5110filgrastim-aafi
    Covered HCPCS Codes (oncology / ophthalmic)HCPCS
    J9185fludarabine phosphate
    J7311fluocinolone acetonide (RETISERT)
    J7313fluocinolone acetonide (ILUVIEN)
    J7314fluocinolone acetonide (YUTIQ)
    HCPCS / J-codes present in listHCPCS
    J9185fludarabine phosphate
    J7311fluocinolone acetonide (RETISERT)
    J7313fluocinolone acetonide (ILUVIEN)
    J7314fluocinolone acetonide (YUTIQ)
    J8499fluoxetine / multiple other oral agents listed under J8499
    J8999various oral oncology agents (e.g., flutamide, fruquintinib, gilteritinib, glasdegib)
    S0128follistim
    S0126follistim / follitropin alfa
    J1434fosaprepitant
    J1453fosaprepitant (EMEND)
    1–10 of 37
    1/4
    Drug HCPCS codes (examples)HCPCS
    J1620gonadorelin
    Drug HCPCS codes (examples)HCPCS
    J0725chorionic gonadotropin
    J3355urofollitropin
    J9202goserelin acetate implant
    HCPCS and related codes from this partHCPCS
    J8499various pharmacy/administered drugs (placeholder)
    J1627granisetron - subcutaneous
    J1628guselkumab
    J1640hemin
    J9226histrelin acetate
    J1746ibalizumab-uiy
    J1740ibandronate sodium
    J8999oral/other oncology or pharmacy-coded drugs (placeholder)
    J1744icatibant acetate
    J9211idarubicin hcl - inj
    1–10 of 18
    1/2
    Listed HCPCS codes (partial)HCPCS
    J0588incobotulinumtoxin a
    J1823inebilizumab-cdon
    J1745infliximab
    Listed HCPCS/Q-codes (infliximab biosimilars)HCPCS
    Q5104infliximab-abda
    Q5121infliximab-axxq
    J1748infliximab-dyyb
    Q5103infliximab-dyyb (alternate code)
    Additional HCPCS/J-codes (partial, many listed with J8499 or J8999 placeholders)HCPCS
    C9399inotersen sodium (and other miscellaneous drug codes)
    J9229inotuzumab ozogamicin
    J3490insulin / levalbuterol inhaler / ketorolac ophthalmic (miscellaneous)
    J1826interferon beta-1a
    Q3027interferon beta-1a (alternate)
    Q3028interferon beta-1a/albumin (alternate)
    J1830interferon beta-1b
    J9216interferon gamma-1b
    J9228ipilumumab
    J8499multiple oral/systemic drugs listed as J8499 (miscellaneous)
    1–10 of 18
    1/2
    Listed HCPCS/Codes near leuprolide entriesHCPCS
    J9217
    J9218
    J1954leuprolide acetate (lutrate)
    J1950leuprolide acetate/norethindrone (LUPANETA PACK)
    J1952leuprolide mesylate
    Miscellaneous HCPCS/CodesHCPCS
    J9003leuprolide mesylate
    J3490levalbuterol inhaler / lifitegrast / liraglutide / others as placeholder unclassified
    J8499multiple pharmacy drugs billed with J8499
    J0641levoleucovorin (FUSILEV)
    Oncology and specialty HCPCS/CodesHCPCS
    J9601linvoseltamab-gcpt
    C9307linvoseltamab-gcpt (alternate)
    J9153liposome-encapsulated combination of daunorubicin and cytarabine (VYXEOS)
    J3490liraglutide placeholder
    Radiopharmaceuticals and injectablesHCPCS
    C9031lutetium lu 177 dotatate (LUTATHERA)
    A9513lutetium lu 177 dotatate
    A9607lutetium lu 177 vipivotide tetraxetan
    Cytotoxics and fertility agentsHCPCS
    J9999mechlorethamine - topical (VALCHLOR) / misc unclassified
    C9080melphalan flufenamide hcl (PEPAXTO)
    J9246melphalan hcl - inj (EVOMELA)
    J9248melphalan hcl - inj (HEPZATO KIT)
    J9249melphalan hcl - inj (apotex)
    Sample codes (methotrexate entries)HCPCS
    J9250methotrexate/pf HCPCS code listed
    J9260methotrexate sodium HCPCS code listed
    J9255methotrexate sodium (accord) HCPCS code listed
    Sample codes (various agents)HCPCS
    J0887methoxy peg-epoetin beta HCPCS codes listed (J0887 J0888)
    J0888methoxy peg-epoetin beta HCPCS codes listed (J0887 J0888)
    J8499multiple drugs listed with J8499 placeholder
    J3490multiple drugs listed with J3490 placeholder
    Additional HCPCS codesHCPCS
    J2267mirikizumab-mrkz HCPCS
    J9063mirvetuximab soravtansine-gynx HCPCS
    J9299nivolumab HCPCS
    J9298nivolumab and relatlimab-rmbw HCPCS
    Selected HCPCS/J-codes from listHCPCS
    J9256nipocalimab-aahu
    J8999niraparib (oral) and other oral oncology agents listed with J8999
    J8499multiple drugs assigned to J8499 (various oral or pharmacy drugs)
    J9299nivolumab
    J9298nivolumab and relatlimab-rmbw
    J9289nivolumab and hyaluronidase-nvhy
    J9028nogapendekin alfa inbakicept-pmln
    C9169nogapendekin alfa inbakicept-pmln (alternate)
    J2326nusinersen
    C9301obecabtagene autoleucel
    1–10 of 11
    1/2
    Additional HCPCS/J-codesHCPCS
    J2350ocrelizumab (IV)
    J2351ocrelizumab and hyaluronidase-ocsq (SQ)
    J2353octreotide acetate, mi-spheres (Sandostatin LAR / depot)
    J2354octreotide non-depot
    J9302ofatumumab
    J9267paclitaxel
    J9258paclitaxel (albumin-bound)
    J9264paclitaxel (albumin-bound) alternate code
    Other HCPCS/J-codesHCPCS
    J8499used repeatedly for many oral or pharmacy items (e.g., omeprazole packets, palbociclib - oral listed with J8999 in other rows)
    J9263oxaliplatin
    J2425palifermin
    90378palivizumab
    J9303panitumumab
    Coding — summary
    Key coding groupsSee code groups table for all listed HCPCS/J/Q/C codes in document (multiple groups across sections).
    Most common placeholdersJ8499 and J8999 are used frequently as miscellaneous/oral placeholders across entries.
    Benefit assignmentEach drug entry lists Benefit Type (P = Pharmacy or M = Medical) next to the drug name.
    Reviewer optionsReviewer assigned per drug (ESI, CCUM, eviCore) with WPS as fallback if external reviewer cannot complete review.
    Effective Date (coding)
    Effective date4/1/2026
    Applies toCoding entries and listed drug pages that include HCPCS/J/Q/C codes.
    Document noteMultiple sections repeat 'Effective Date: 4/1/2026' near code listings.
    Effective Date (coding)
    Effective date4/1/2026
    Referenced sectionCoding thresholds and specific code groups near chunk 170.
    Reviewer mappingEntries in this area show reviewer assignments (e.g., CCUM option 2).
    Effective Date (coding)
    Effective date4/1/2026
    Applies toAdditional HCPCS/J-code listings and related coding groups in these chunks.
    Reviewer noteMany entries here indicate CCUM or eviCore as reviewer with WPS contact provided.
    Prior Authorization

    Prior authorization required

    All drugs in these sections require prior authorization; if ESI, CCUM, or eviCore cannot complete the delegated review, submit the PA to WPS for evaluation.

    • Route medical-benefit submissions using the HCPCS/J-code provided and the reviewer specified for that drug.
    • If the external reviewer cannot complete the review, submit to WPS at 1-800-333-5003.
    Prior Authorization

    Prior authorization requirement

    Every drug listed in these chunks requires prior authorization and should be routed to the reviewer indicated (ESI/CCUM/eviCore) shown for each drug entry.

    • Follow reviewer routing options: ESI (option 1), CCUM (option 2), eviCore (option 3).
    • If the designated vendor cannot complete the review, submit to WPS for evaluation.
    Prior Authorization

    Prior authorization required

    Submit prior authorization requests for the drugs in these segments to the designated reviewer (ESI, CCUM, eviCore, or WPS) shown next to each drug; if an external reviewer cannot complete the review, escalate to WPS.

    • Use the phone number 1-800-475-1954 to contact ESI/CCUM/eviCore; use 1-800-333-5003 for WPS.
    • Provide the HCPCS code and benefit type (P or M) when submitting.
    Billing Rule

    All listed drugs require PA

    Prior authorization is required for each listed drug; for medical-benefit drugs submit using the HCPCS/J-code shown and for pharmacy-benefit drugs follow PBM routing indicated in the entry.

    • Medical benefit claims: bill using the HCPCS/J-code provided for facility/provider billing.
    • Pharmacy benefit drugs: submit to the PBM indicated (e.g., ESI) or the group's PBM per policy notes.
    Prior Authorization

    PA required; reviewer routing

    PA is required for the drugs shown; route requests to the named reviewer vendor (ESI, CCUM, eviCore) or submit to WPS when the PBM cannot complete the review.

    • Use reviewer routing as listed for each drug entry.
    • If delegated reviewer cannot complete review, submit to WPS at 1-800-333-5003.
    Prior Authorization

    PA required; codes and reviewer assignment

    Prior authorization is required for each listed drug; each entry includes HCPCS/J/Q/C codes and the assigned reviewer (ESI, CCUM, or eviCore) to which the PA must be submitted.

    • Include the HCPCS/J/Q/C code shown in the drug entry when submitting the PA.
    • Route the PA to the reviewer vendor listed for that drug (contact 1-800-475-1954).
    Prior Authorization

    PA required; submit to delegated reviewer

    All drugs in these chunks require prior authorization; submit requests to the delegated reviewer indicated (ESI, CCUM, eviCore) or to WPS if the delegated reviewer cannot complete the review.

    • Follow delegated reviewer instructions per drug entry.
    • If reviewer cannot complete review, forward PA to WPS for evaluation.
    Prior Authorization

    Prior authorization required

    All drugs listed in these chunks require prior authorization; reviewer assignment (ESI, CCUM, eviCore, or WPS) is indicated for each drug entry and must be followed when submitting the PA.

    • Benefit Type field indicates Pharmacy (P) or Medical (M); route accordingly.
    • If the external reviewer cannot complete the review, submit to WPS.
    Prior Authorization

    Prior authorization required

    Prior authorization is required for each drug entry; submit requests to the reviewer listed for that drug (ESI, CCUM, eviCore) or to WPS if external reviewers cannot complete the review.

    • Include the HCPCS code shown and specify oncology vs non-oncology indication so the correct reviewer is engaged.
    • Use external reviewer contact 1-800-475-1954 or WPS at 1-800-333-5003 as needed.
    Prior Authorization

    PA required for listed drugs

    Prior authorization is required for each drug entry; submit the PA to the reviewer listed for that drug (ESI, CCUM, eviCore, or WPS) using the contact routing provided in the policy.

    • Provide drug name, HCPCS/J-code, and benefit type when submitting the request.
    • If the delegated reviewer cannot complete the review, escalate to WPS for evaluation.
    Documentation Required

    PA required; reviewer contacts

    All drugs listed require prior authorization; the document provides reviewer phone numbers (ESI/CCUM/eviCore and WPS) to request PA and indicates which reviewer to contact per drug.

    • Primary reviewer contact for delegated reviewers: 1-800-475-1954.
    • WPS PA phone: 1-800-333-5003.
    Prior Authorization

    PA required; submit to delegated reviewer

    Prior authorization is required for the drugs shown; submit PA requests to the delegated reviewer (ESI, CCUM, eviCore) or to WPS when the reviewer cannot complete the review.

    • Use the HCPCS code listed for the drug when submitting medical-benefit requests.
    • If delegated reviewer cannot complete review, send the PA to WPS for evaluation.
    Prior Authorization

    PA required; reviewer and code listed

    Each listed drug requires prior authorization; the entry includes HCPCS/J-codes and the reviewer contact (ESI, CCUM, eviCore) to which the PA must be submitted.

    • Include HCPCS/J-code from the drug entry in the PA submission.
    • Route to the reviewer shown for that drug (contact 1-800-475-1954) or to WPS if necessary.
    Step Therapy

    How to obtain PA/step therapy criteria

    Step therapy and prior authorization criteria for drugs reviewed by Express Scripts or Care Continuum are available by calling 1-800-475-1954; eviCore criteria are available at evicore.com.

    • Call 1-800-475-1954 to speak with a prior authorization specialist for ESI/CCUM criteria.
    • For eviCore guidelines, go to https://www.evicore.com/provider/clinical-guidelines and search 'WPS Health Insurance'.
    Note

    PBM submission note

    If your group uses a PBM other than Express Scripts through WPS, submit prior authorization requests to that PBM; this includes pharmacy drugs that may otherwise be reviewed by ESI or eviCore.

    • When a different PBM is in place, follow that PBM's PA submission process for pharmacy-benefit drugs.
    • If the external reviewer cannot complete the review, submit the PA to WPS for evaluation.
    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    PBM routing: submit to the group's PBM when not ESI

    If your group's PBM is not Express Scripts through WPS, submit PAs to that PBM; pharmacy drugs reviewed by ESI or eviCore may be handled by those vendors when they are the group's PBM.

    • Confirm which PBM is responsible for pharmacy-benefit reviews before submitting a PA.
    • When in doubt, contact WPS for routing instructions.
    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    PBM routing note

    If your group's PBM is not Express Scripts through WPS, submit prior authorization requests to that PBM for pharmacy-benefit drugs; entries in this policy note that some pharmacy drugs may be reviewed by ESI or eviCore when those vendors are the PBM.

    • Verify the PBM responsible for the member's coverage before submitting a pharmacy PA.
    • If delegated reviewer cannot complete the review, submit to WPS for evaluation.
    Note

    Provider action

    —

    Note

    Provider action

    —

    Note

    Provider action

    —

    Documentation Required

    Evidence reviewers use in PA decisions

    Reviewers use the patient's medical records, FDA labeling, peer‑reviewed literature, and evidence‑based guidelines when making prior authorization decisions.

    • Provide medical records describing the patient's condition and prior treatments with the PA submission.
    • FDA labeling and relevant literature may be requested during review.
    Documentation Required

    AHH fax for AETNA network groups

    For WPS Powered by Auxiant groups using the AETNA network, fax medical notes for recommended medical necessity review of medical‑benefit drugs to American Health Holdings (AHH) at 608-273-4554 prior to administration.

    • Fax medical documentation to AHH at 608-273-4554 for AETNA network medical‑benefit drugs.
    • A medical necessity review is recommended even when a separate PA is not required under the medical benefit.
    Documentation Required

    Where to submit PA

    Submit prior authorization requests to the reviewer listed for each drug (ESI, CCUM, or eviCore); if those reviewers cannot complete the review, submit the PA to WPS for evaluation.

    • Use reviewer contact 1-800-475-1954 for ESI/CCUM/eviCore and 1-800-333-5003 for WPS.
    • Include drug name, HCPCS/J-code, benefit type, and indication when submitting.
    Documentation Required

    Where to submit PA

    Submit PA requests to the reviewer shown for each drug or to WPS if external reviewers cannot complete the review; follow the contact numbers and routing indicated in the drug entry.

    • Contact external reviewers at 1-800-475-1954; contact WPS at 1-800-333-5003 if needed.
    • If a PBM other than ESI is in effect, submit to that PBM for pharmacy-benefit drugs.
    Documentation Required

    Where to submit PA

    Submit prior authorization requests to the designated reviewer shown for each drug using the contact numbers listed; if the PBM is not ESI through WPS or the external reviewer cannot complete the review, submit to WPS for evaluation.

    • Provide benefit type (P or M) and HCPCS code when submitting.
    • When the external reviewer is unable to review, route to WPS at 1-800-333-5003.
    Documentation Required

    Where to submit PA

    Submit prior authorization requests to the reviewer indicated for each drug using the phone numbers provided; if the PBM or delegated reviewer cannot complete review, submit the PA to WPS for evaluation.

    • Primary reviewer phone: 1-800-475-1954 (ESI/CCUM/eviCore).
    • WPS phone: 1-800-333-5003 for escalations or when reviewers cannot complete review.
    Documentation Required

    Submission routing and contact

    Submit prior authorization requests to the reviewer vendor listed for the drug (ESI, CCUM, eviCore) or to WPS if the vendor cannot complete the review; vendor contact numbers are provided in the policy.

    • Include the HCPCS/J-code and indication to ensure correct routing.
    • If the vendor is unable to complete review, forward to WPS for evaluation.
    Documentation Required

    Submission routing and contact

    Provider must submit PA requests to the listed reviewer (ESI, CCUM, eviCore) or to WPS if the PBM cannot complete the review; contact numbers for reviewers and WPS are provided.

    • When submitting, specify drug name, HCPCS code, benefit type, and indication.
    • If your group's PBM differs from ESI, follow that PBM's submission instructions.
    Documentation Required

    Submission routing and contact

    Providers must submit PA requests to the referenced reviewer (ESI, CCUM, or eviCore) or to WPS if the reviewer cannot complete the review; contact numbers are provided in the policy.

    • Use 1-800-475-1954 to reach delegated reviewers; use 1-800-333-5003 for WPS escalations.
    • Include the HCPCS/J-code and benefit type in submissions.
    Documentation Required

    Where to submit PA

    Submit PA to the listed reviewer (ESI, CCUM, eviCore) or to WPS if the delegated reviewer cannot complete the review; contact numbers are provided in the policy.

    • Follow the reviewer assignment shown next to each drug entry.
    • Escalate to WPS when reviewers cannot complete the review.
    Documentation Required

    Submission pathway when delegated reviewer cannot complete review

    If ESI, CCUM, or eviCore cannot complete the delegated review, submit the prior authorization request to WPS for evaluation.

    • Contact WPS at 1-800-333-5003 for submission when external reviewers cannot complete review.
    • Include the original reviewer information and documentation when resubmitting to WPS.
    Documentation Required

    Where to submit PA

    Submit PA requests to the designated reviewer listed for each drug; if the reviewer cannot complete the review, submit the PA to WPS for evaluation using the contact information provided.

    • Provide drug name, HCPCS code, benefit type, and indication with the request.
    • Use 1-800-475-1954 for delegated reviewers and 1-800-333-5003 for WPS.
    Documentation Required

    Where to submit PA

    Submit prior authorization requests to ESI, CCUM, or eviCore as indicated for each drug; if those reviewers cannot complete the review, submit the PA to WPS for evaluation.

    • Include HCPCS/J-code and whether the indication is oncology or non‑oncology to route correctly.
    • If the delegated reviewer cannot complete the review, escalate to WPS.
    Documentation Required

    Submit to appropriate reviewer or WPS

    Submit PA requests to ESI, CCUM, or eviCore as indicated; if those reviewers cannot complete the review, submit to WPS for evaluation.

    • Contact 1-800-475-1954 for delegated reviewer assistance; contact WPS at 1-800-333-5003 for escalations.
    • Provide required submission details shown in the policy (drug name, HCPCS code, benefit type).
    Documentation Required

    Submit to appropriate reviewer or WPS

    When external vendors cannot complete the review, providers must submit the PA to WPS for evaluation; contact numbers for ESI/CCUM/eviCore (1-800-475-1954) and WPS (1-800-333-5003) are provided.

    • Escalate to WPS if delegated reviewer cannot complete review.
    • Include original reviewer details and all supporting documentation when resubmitting.
    Documentation Required

    Required submission details

    For each listed drug include the drug name, appropriate HCPCS/J-code when applicable, benefit type (Pharmacy or Medical), and indicate if the request is for an oncology or non‑oncology indication so the correct reviewer can be engaged.

    • Provide HCPCS/J-code and benefit type P or M on the submission.
    • State the indication (oncology vs non‑oncology) to ensure proper routing.
    Documentation Required

    Where to submit PA

    Submit PA requests to the designated reviewer (ESI, CCUM, or eviCore) or to WPS if the PBM cannot complete the review.

    • Confirm which reviewer is responsible for the drug and use the contact provided in the policy.
    • If the PBM cannot complete review, forward to WPS for evaluation.
    Denial Risk

    Medical necessity and experimental exclusions

    Coverage of services is subject to medical necessity; services deemed experimental, investigational, or unproven will not be covered under the policy.

    • Ensure requested treatment meets the plan's medical necessity criteria.
    • Experimental or investigational services are not eligible for coverage.
    Denial Risk

    PA required

    Lack of a prior authorization (PA) for any drug listed on this policy will trigger the need for review; drugs on the list require a PA before coverage is approved.

    • Do not administer or bill for listed drugs without obtaining the required PA.
    • If PA is not obtained, coverage may be denied.
    Denial Risk

    PA requirement

    Failure to obtain prior authorization (PA) for any drug on the list may result in denial of coverage; providers must secure the PA and submit as directed.

    • Claims submitted without required PA are at risk for denial.
    • Follow the reviewer routing and submission requirements to avoid denials.
    Denial Risk

    PA required for listed drugs

    Failure to obtain prior authorization (PA) for any drug on the list will risk denial; all drugs on this list require a PA and must be submitted to the appropriate reviewer or to WPS if reviewers cannot complete the review.

    • Ensure PA is approved before dispensing or administering listed drugs.
    • If the delegated reviewer cannot complete review, submit to WPS to avoid processing delays or denial.
    Denial Risk

    PA required for listed drugs

    Failure to obtain prior authorization for any drug on the list will risk denial, since the document states all drugs on this list require a PA.

    • Confirm PA approval prior to treatment.
    • Follow PBM routing instructions where applicable.
    Denial Risk

    All listed drugs require PA

    Failure to obtain prior authorization for any drug on the list may result in denial; all drugs on this list require a PA and must be submitted to the designated reviewer or to WPS if the vendor cannot complete review.

    • Use HCPCS/J-codes for medical‑benefit submissions as shown.
    • Route pharmacy‑benefit drugs per PBM assignment to avoid denials.
    Denial Risk

    PA required

    Failure to obtain prior authorization for any drug listed may lead to denial of coverage; all drugs on this list require a PA before approval.

    • Obtain PA prior to providing therapy to prevent claim denials.
    • If external reviewer cannot complete review, submit to WPS for evaluation.
    Denial Risk

    PA required for listed drugs

    No PA will be processed without prior authorization; all drugs on this list require a PA and, if ESI, CCUM, or eviCore cannot complete the review, submit to WPS for evaluation.

    • Submit PA to the delegated reviewer first; if they cannot complete review, forward to WPS.
    • Claims without required PA are subject to denial.
    Denial Risk

    Prior authorization required

    Failure to obtain prior authorization will risk denial since 'All drugs on this list require a PA.'

    • Confirm PA approval before administering or billing for listed drugs.
    • Escalate to WPS if delegated reviewer cannot complete the review.
    Denial Risk

    PA required

    Claims for any drug on this list will require prior authorization; failure to obtain PA may result in denial of coverage.

    • Ensure PA is obtained and approved prior to service.
    • Provide all requested documentation to the reviewer to support medical necessity.
    Prior Authorization

    PA required

    No prior authorization will be approved for listed drugs without submission to the appropriate reviewer (ESI, CCUM, eviCore) or to WPS when those reviewers cannot complete review.

    • Submit to the reviewer specified for the drug; if unable, submit to WPS for evaluation.
    • Provide HCPCS/J-code and indication to the reviewer.
    Denial Risk

    PA required

    Failure to obtain prior authorization (PA) for any drug on this list may lead to denial; all drugs on this list require a PA.

    • Obtain PA prior to treatment to reduce risk of denial.
    • Follow the reviewer routing specified in the policy.
    Denial Risk

    PA required for listed drugs

    Failure to submit a required prior authorization (PA) for any drug on the listed pages may result in denial of coverage or claim processing issues; all drugs on this list require a PA.

    • Include required documentation with the PA to avoid processing delays.
    • If the reviewer cannot complete the review, resubmit to WPS.
    Denial Risk

    PA required for listed drugs

    Failure to submit a prior authorization (PA) for any drug on this list will risk denial of coverage; all drugs on this list require a PA and must be submitted as directed.

    • Submit PAs following the routing and contact information in the policy.
    • Ensure HCPCS/J-code and indication are clearly stated in submissions.
    Fallback
    If external reviewers cannot complete review, submit to WPS for evaluation.
    Reviewer routing
    Routing optionsESI (option 1), CCUM (option 2), eviCore (option 3).
    Fallback instructionIf delegated reviewer cannot complete review, providers must submit the PA to WPS for evaluation.
    ContactExternal reviewer phone: 1-800-475-1954; WPS phone: 1-800-333-5003.
    Benefit Type — key
    Benefit Type keyP = Pharmacy; M = Medical.
    Displayed whereShown next to each drug entry to indicate billing benefit.
    ImplicationMedical (M) entries typically include HCPCS codes for facility/provider billing.
    Reviewer — definition
    PurposeIndicates which external PBM or utilization management vendor (ESI, CCUM, eviCore) will perform the PA review.
    Document showsReviewer assignments are listed per drug entry; contact numbers are provided for routing.
    When unclearIf drug/indication is not reviewed by external vendors, submit to WPS for evaluation.
    Benefit Type (alternate)
    Benefit Type mappingBenefit Type P = Pharmacy; M = Medical (appears repeatedly across entries).
    Shown next to drugUsed to indicate billing route and reviewer selection per drug entry.
    NoteFor PBM arrangements not using ESI through WPS, submit to the group's PBM as instructed in entries.
    Reviewer — assignments
    Reviewer assignmentsESI (option 1), CCUM (option 2), eviCore (option 3).
    If unable to completeIf delegated reviewers cannot complete review, submit to WPS for evaluation.
    Routing detailSome entries specify oncology vs non-oncology routing between CCUM and eviCore.
    Benefit Type — indicator
    Benefit Type indicatorIndicates whether the drug benefit is Pharmacy (P) or Medical (M) as listed next to each drug.
    UsageDetermines whether pharmacy PBM or medical-review pathways and HCPCS codes apply.
    ExamplesMultiple entries show 'Benefit Type P = Pharmacy** M = Medical = P' or similar formatting.